@article {836756,
	title = {Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.},
	journal = {Ocul Immunol Inflamm},
	year = {2016},
	month = {2016 Jul 20},
	pages = {1-6},
	abstract = {PURPOSE: To describe clinical manifestations, diagnostic approaches, therapy, and outcomes of biopsy-proven intraocular lymphoma. METHODS: Review of tertiary referral center records between 2005 and 2015. RESULTS: A total of 51 eyes of 26 patients were included; mean age of onset was 60.42 years. Common ocular complaints included floaters (42\%) and blurred vision (35\%); 62\% of patients had ocular and central nervous system involvement; 11\% had systemic lymphoma; and 27\% had only ocular involvement. Vitreous analysis was positive for malignant cells in 77\% of patients on initial biopsy, and in 100\% of patients on repeat biopsy. In total, 20/26 patients received systemic and topical treatment before IOL diagnosis was made; 25 patients received intravitreal methotrexate and/or rituximab; one patient received intracameral rituximab. All patients achieved remission by their final visit. CONCLUSIONS: Intraocular lymphoma often masquerades as intraocular inflammation, resulting in delayed or misdiagnosis with subsequent inappropriate management. Optimal therapy is a challenge for oncologists and ophthalmologists.},
	issn = {1744-5078},
	doi = {10.1080/09273948.2016.1193206},
	author = {Abusamra, Khawla and Oray, Merih and Ebrahimiadib, Nazanin and Lee, Stacey and Anesi, Stephen and Foster, C Stephen}
}
